<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564002</url>
  </required_header>
  <id_info>
    <org_study_id>2017-12</org_study_id>
    <nct_id>NCT03564002</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Very Low Carbohydrate Ketogenic Diet in Subjects With Severe Obesity</brief_title>
  <official_title>Metabolic Effects of Very Low Carbohydrate Ketogenic Diet in Subjects With Severe Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The very low carbohydrates diet (VLCKD) induces liver steatosis amelioration. Lysosomal acid
      lipase (LAL) deficiency plays a role in fats accumulation in liver. To date, no studies have
      assessed LAL activity in morbid obesity. The aim of our study is to evaluate VLCKD impact on
      metabolic/vascular parameters and LAL activity in obese patients.

      A VLCKD is administered for 25 days to 52 morbid obese patients (BMI 44.7±8.3 kg/m², age
      49±12.5 years); at baseline and after diet we evaluated: BMI, glyco-lipidic pattern,
      abdominal ultrasonography (liver steatosis and visceral fat area) and flow-mediated dilation
      (FMD). In a subgroup of 20 patients we also tested lysosomal acid lipase (LAL)-activity. A
      group of healthy normal weight subjects (age 43±13, BMI 22.8±2.6 kg/m²) was also included in
      the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>lysosomal acid lipase activity</measure>
    <time_frame>change from baseline after 25 days</time_frame>
    <description>LAL-activity was dosed with dried blood spot (DBS) technique using the inhibitors Lalistat 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>endothelial function</measure>
    <time_frame>change from baseline after 25 days</time_frame>
    <description>flow mediated dilation at brachial artery by ultrasonography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>visceral fat</measure>
    <time_frame>change from baseline after 25 days</time_frame>
    <description>ultrasonography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>liver steatosis</measure>
    <time_frame>change from baseline after 25 days</time_frame>
    <description>ultrasonography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lipid assessment</measure>
    <time_frame>change from baseline after 25 days</time_frame>
    <description>total cholesterol, triglycerides, HDL, LDL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>general adiposity assessment</measure>
    <time_frame>change from baseline after 25 days</time_frame>
    <description>bioimpedentiometry</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lysosomal Acid Lipase Deficiency</condition>
  <condition>Obesity</condition>
  <condition>Ketogenic Dieting</condition>
  <condition>Ketosis</condition>
  <arm_group>
    <arm_group_label>obese subjects</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>lean subjects</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        obese patients referred to our Clinic in order to assess and treat obesity
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt; 40 Kg/m2 or &gt; 35 kg/m2 with comorbidities

        Exclusion Criteria:

          -  Type-2 diabetes

          -  Kidney, heart or liver failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Graziana Lupattelli, Professor</last_name>
    <phone>+390755784023</phone>
    <email>graziana.lupattelli@unipg.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Perugia</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graziana Lupattelli, Prof</last_name>
      <phone>+390755784023</phone>
      <email>graziana.lupattelli@unipg.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Maria Anastasia Ricci</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wolman Disease</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

